HALIFAX, Nov. 12, 2013 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, today announced a collaborative research agreement with the National Research Council of Canada (NRC). MedMira is aiming to advance its rapid diagnostic technology through the creation of a next generation rapid diagnostics platform, specifically for diseases and conditions which today can only be diagnosed using traditional laboratory based tests, processes, and equipment.
MedMira will receive funding support towards this research from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). MedMira and NRC will work together over a 10 month period on two key areas that will expand the capabilities of MedMira's rapid diagnostic technology platform. The first will develop new nanoparticles that are more visible than traditional particles, allowing earlier diagnosis of diseases. In addition to making the detection more sensitive it also broadens the scope of applications that can be built on the rapid flow-through technology platform. With these advancements, certain diseases and medical conditions, which today may be below the detection limits for all rapid assays, could soon be detected in minutes, at the point-of-care, using a MedMira rapid test.
"This is a valuable opportunity to bring together research and development efforts from both MedMira and the National Research Council to deliver superior healthcare tools more rapidly than we could alone," said Dr. Neeraj Vats, Director of Technology and Business Affairs, MedMira Inc.
The second advancement will involve NRC and MedMira conducting research and development activities leading to the addition of non-visual detection in the rapid diagnostic platform. Automating the reading and recording of test results brings significant operational efficiencies to healthcare providers, faster treatment for patients, and better surveillance data in large scale screening programs run by health departments and aid organizations.
Dr. Vats added "In addition to broadening the scope of applications that can be created on rapid tests, we are also working to enhance the user experience. The development of simple instrumentation that can interpret, record and transmit results in real-time to specialists that can determine treatment options will be very powerful, and mean that specialists no longer have to be in the same room or the same country as their patient, which will enable better care."
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The Company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MEDMIRA INC.
For further information:
Andrea Young, Corporate Communications
E. [email protected]